Anticancer drug treatment for advanced lung cancer with interstitial lung disease

Kohei Otsubo, Isamu Okamoto, Naoki Hamada, Yoichi Nakanishi

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Interstitial lung disease (ILD) is a risk factor for lung cancer development and is frequently observed in patients with lung cancer. Individuals with ILD have been excluded from most prospective clinical trials of lung cancer therapies because of the risk of ILD acute exacerbation. Thus, the optimal anticancer drug treatment for such patients has yet to be established. Tyrosine kinase inhibitors are avoided for the treatment of advanced non–small cell lung cancer (NSCLC) with ILD because of the concern of acute exacerbation, and information on the effects of immune-checkpoint inhibitors is limited in these patients. Only three prospective single-arm studies of cytotoxic chemotherapies for advanced lung cancer with ILD have been reported. Based on the results of these studies and those of retrospective analyses, carboplatin and either paclitaxel or nab-paclitaxel are often selected in daily clinical practice for patients with NSCLC and ILD, whereas platinum plus etoposide is selected for those with small cell lung cancer and ILD. Although the antitumor activity of first-line platinum-based chemotherapy appears similar in advanced lung cancer patients with and without ILD, its impact on overall survival of the former patients is limited. The risks and benefits of chemotherapy must therefore be carefully explained before treatment initiation, and careful follow-up is necessary for such patients, especially those with the usual interstitial pneumonia pattern, a risk factor for chemotherapy-related exacerbation. Prospective clinical studies with large patient populations are still required to establish the appropriate treatments for advanced lung cancer with ILD.

Original languageEnglish
Pages (from-to)307-311
Number of pages5
JournalRespiratory Investigation
Volume56
Issue number4
DOIs
Publication statusPublished - Jul 2018

Fingerprint

Interstitial Lung Diseases
Lung Neoplasms
Pharmaceutical Preparations
Drug Therapy
Therapeutics
Platinum
Non-Small Cell Lung Carcinoma
Idiopathic Pulmonary Fibrosis
Carboplatin
Small Cell Lung Carcinoma
Etoposide
Paclitaxel
Protein-Tyrosine Kinases
Disease Progression
Retrospective Studies
Clinical Trials
Prospective Studies
Survival

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Anticancer drug treatment for advanced lung cancer with interstitial lung disease. / Otsubo, Kohei; Okamoto, Isamu; Hamada, Naoki; Nakanishi, Yoichi.

In: Respiratory Investigation, Vol. 56, No. 4, 07.2018, p. 307-311.

Research output: Contribution to journalReview article

@article{64d96edbaa0d472897e1f3ce22154576,
title = "Anticancer drug treatment for advanced lung cancer with interstitial lung disease",
abstract = "Interstitial lung disease (ILD) is a risk factor for lung cancer development and is frequently observed in patients with lung cancer. Individuals with ILD have been excluded from most prospective clinical trials of lung cancer therapies because of the risk of ILD acute exacerbation. Thus, the optimal anticancer drug treatment for such patients has yet to be established. Tyrosine kinase inhibitors are avoided for the treatment of advanced non–small cell lung cancer (NSCLC) with ILD because of the concern of acute exacerbation, and information on the effects of immune-checkpoint inhibitors is limited in these patients. Only three prospective single-arm studies of cytotoxic chemotherapies for advanced lung cancer with ILD have been reported. Based on the results of these studies and those of retrospective analyses, carboplatin and either paclitaxel or nab-paclitaxel are often selected in daily clinical practice for patients with NSCLC and ILD, whereas platinum plus etoposide is selected for those with small cell lung cancer and ILD. Although the antitumor activity of first-line platinum-based chemotherapy appears similar in advanced lung cancer patients with and without ILD, its impact on overall survival of the former patients is limited. The risks and benefits of chemotherapy must therefore be carefully explained before treatment initiation, and careful follow-up is necessary for such patients, especially those with the usual interstitial pneumonia pattern, a risk factor for chemotherapy-related exacerbation. Prospective clinical studies with large patient populations are still required to establish the appropriate treatments for advanced lung cancer with ILD.",
author = "Kohei Otsubo and Isamu Okamoto and Naoki Hamada and Yoichi Nakanishi",
year = "2018",
month = "7",
doi = "10.1016/j.resinv.2018.03.002",
language = "English",
volume = "56",
pages = "307--311",
journal = "Respiratory Investigation",
issn = "2212-5345",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Anticancer drug treatment for advanced lung cancer with interstitial lung disease

AU - Otsubo, Kohei

AU - Okamoto, Isamu

AU - Hamada, Naoki

AU - Nakanishi, Yoichi

PY - 2018/7

Y1 - 2018/7

N2 - Interstitial lung disease (ILD) is a risk factor for lung cancer development and is frequently observed in patients with lung cancer. Individuals with ILD have been excluded from most prospective clinical trials of lung cancer therapies because of the risk of ILD acute exacerbation. Thus, the optimal anticancer drug treatment for such patients has yet to be established. Tyrosine kinase inhibitors are avoided for the treatment of advanced non–small cell lung cancer (NSCLC) with ILD because of the concern of acute exacerbation, and information on the effects of immune-checkpoint inhibitors is limited in these patients. Only three prospective single-arm studies of cytotoxic chemotherapies for advanced lung cancer with ILD have been reported. Based on the results of these studies and those of retrospective analyses, carboplatin and either paclitaxel or nab-paclitaxel are often selected in daily clinical practice for patients with NSCLC and ILD, whereas platinum plus etoposide is selected for those with small cell lung cancer and ILD. Although the antitumor activity of first-line platinum-based chemotherapy appears similar in advanced lung cancer patients with and without ILD, its impact on overall survival of the former patients is limited. The risks and benefits of chemotherapy must therefore be carefully explained before treatment initiation, and careful follow-up is necessary for such patients, especially those with the usual interstitial pneumonia pattern, a risk factor for chemotherapy-related exacerbation. Prospective clinical studies with large patient populations are still required to establish the appropriate treatments for advanced lung cancer with ILD.

AB - Interstitial lung disease (ILD) is a risk factor for lung cancer development and is frequently observed in patients with lung cancer. Individuals with ILD have been excluded from most prospective clinical trials of lung cancer therapies because of the risk of ILD acute exacerbation. Thus, the optimal anticancer drug treatment for such patients has yet to be established. Tyrosine kinase inhibitors are avoided for the treatment of advanced non–small cell lung cancer (NSCLC) with ILD because of the concern of acute exacerbation, and information on the effects of immune-checkpoint inhibitors is limited in these patients. Only three prospective single-arm studies of cytotoxic chemotherapies for advanced lung cancer with ILD have been reported. Based on the results of these studies and those of retrospective analyses, carboplatin and either paclitaxel or nab-paclitaxel are often selected in daily clinical practice for patients with NSCLC and ILD, whereas platinum plus etoposide is selected for those with small cell lung cancer and ILD. Although the antitumor activity of first-line platinum-based chemotherapy appears similar in advanced lung cancer patients with and without ILD, its impact on overall survival of the former patients is limited. The risks and benefits of chemotherapy must therefore be carefully explained before treatment initiation, and careful follow-up is necessary for such patients, especially those with the usual interstitial pneumonia pattern, a risk factor for chemotherapy-related exacerbation. Prospective clinical studies with large patient populations are still required to establish the appropriate treatments for advanced lung cancer with ILD.

UR - http://www.scopus.com/inward/record.url?scp=85045579261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045579261&partnerID=8YFLogxK

U2 - 10.1016/j.resinv.2018.03.002

DO - 10.1016/j.resinv.2018.03.002

M3 - Review article

C2 - 29764748

AN - SCOPUS:85045579261

VL - 56

SP - 307

EP - 311

JO - Respiratory Investigation

JF - Respiratory Investigation

SN - 2212-5345

IS - 4

ER -